“Health” joins “Green.” From inspired cause to pervasive business imperative, leadership in health and health- issues has emerged as a smart new business strategy that can drive purchasing, loyalty decisions and trust, according to a new 11-country survey of 15,000+ people being released next week at the 7th Annual World Heath Care Congress in Washington, D.C.
New studies show that overweight and obese people using alli® (orlistat 60 mg) with a reduced calorie, lower-fat diet can significantly reduce weight, visceral fat, and waist circumference and therefore may reduce their risk of type 2 diabetes, hypertension, heart disease and stroke. The studies were presented at the 1st International Congress on Abdominal Obesity in Hong Kong earlier today.
Church & Dwight Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the FIRST RESPONSE® Early Result Pregnancy Test which can determine pregnancy up to six days before the day of a woman’s missed period.
Clinical and basic science researchers from around the world will convene in Hong Kong from January 28 to 30 for the First International Congress on Abdominal Obesity: “Bridging the Gap between Cardiology and Diabetology.” The congress, sponsored by the International Chair on Cardiometabolic Risk (ICCR) (www.cardiometabolic-risk.org), is the first-ever specialized forum for sharing new insights and evidence about abdominal obesity and its clinical and public health implications.
Are Americans in denial about their eating habits? Today, two out of three Americans are overweight or obese, and by 2030 that figure will balloon to nearly nine out of 10. Yet in a new national survey, three-quarters of respondents (74%) said they have a healthy personal relationship with food—revealing a clear disconnect between how we think and how we act when it comes to eating. GlaxoSmithKline Consumer Healthcare, the maker of alli®, sponsored the survey to better understand America’s unhealthy relationship with food and develop solutions to help people change the way they eat.
As the healthcare reform debate continues, legislators and businesspeople alike might be surprised to learn that Americans are looking not only to government but also to business to improve our nation’s health, even beyond employee wellness efforts. People are more likely to purchase from, recommend, and invest in companies that act on health issues—creating a compelling case for businesses to step up their efforts.
A new article published in the peer-reviewed journal Women’s Health emphasizes the importance of early pregnancy detection. Using research conducted on behalf of Church & Dwight Co. Inc., the makers of First Response, the article reviews data that shows not all at-home pregnancy tests are created equal –First Response® brand pregnancy tests are more sensitive and able to detect key variants of the pregnancy hormone better than other at home pregnancy tests.
Bausch & Lomb announces the appointment of Mohinder Merchea, O.D., Ph.D., MBA, FAAO, FBCLA, to director of Medical Affairs, North America, Vision Care. Dr. Merchea will serve as the department’s liaison to academic institutions and professional organizations, communicating with key leaders in the field and representing the views of eye care professionals to the company.
Tibotec Therapeutics is launching a new initiative to raise awareness of issues affecting women and people of color living with HIV/AIDS through a comprehensive campaign including local educational events, media outreach and a new Web site, www.TheGraceStudy.com.
Bausch & Lomb today announced that the company’s Lo-Torque® lens design demonstrates significantly better rotational recovery, which can lead to more consistent vision, compared with Acuvue’s accelerated stabilization design.
MedImmune announced today it will present four abstracts at the 47th Annual Meeting of Infectious Disease Society of America (IDSA) being held here October 29 through November 1, 2009. These abstracts advance the body of data surrounding respiratory syncytial virus (RSV) and influenza prevention, highlighting MedImmune’s leadership in pediatric health.
As cough and cold season approaches, new educational materials and PSAs provide important safety information for parents and caregivers
MedImmune announced today it will present four abstracts at the American Academy of Pediatrics (AAP) 2009 National Conference & Exhibition that add to the company’s growing body of research on the burden of respiratory syncytial virus (RSV) on children, as well as pediatric infectious disease prevention.
Company initiates clinical trial for patients with newly-diagnosed glioblastoma multiforme (GBM).
The results of a new clinical study demonstrate that the plaque and gingivitis germ-killing action of LISTERINE® Antiseptic significantly reduces the amount of germs that travel from the mouth to the bloodstream in people with mild to moderate gingivitis. These findings are significant, as emerging science suggests that gingivitis, if left untreated and allowed to progress to advanced gum disease, could contribute to broader health problems such as diabetes, cardiovascular disease, and pneumonia.
Two leading experts in the diagnosis and treatment of fibromyalgia are available for interviews about the signs, symptoms, current treatment landscape and other important aspects of the condition.
Study of nearly 1 million pain medication monitoring tests highlights an important opportunity to improve patient care and doctor-patient communication.
Until now, all regular body washes caused dry skin damage. Now, Dove has discovered how to restore skin's natural moisture while cleansing with body wash. Current body washes actually damage proteins and lipids in the skin's outer layer, often leading to the loss of critical moisture. Recognizing skin lipids require different care than skin proteins, Dove developed its latest liquid cleansing technology called NutriumMoisture. Research published in the June 2009 issue of Cosmetic Dermatology confirms NutriumMoisture is clinically proven to preserve both skin's natural proteins and lipids while significantly reducing dryness and improving moisturization.
MedImmune increases eligibility to its Patient Assistance Program to 400 percent of federal poverty level; as many as 75 percent of U.S. households may now qualify.
MedImmune today announced results from a recent study it sponsored, performed by the Kaiser Permanente Division of Research in Oakland, CA, assessing risk factors for respiratory syncytial virus (RSV) infection requiring medical treatment in infants born at 33 weeks gestational age [GA] or later.
MedImmune has awarded grants to five pediatric fellows to assist their conduct of original research in the field of viral respiratory diseases. For the sixth consecutive year, MedImmune commits $175,000.
Abraxis BioScience presents preclinical and clinical results from 10 studies evaluating chemotherapeutic agent ABRAXANE (R), SPARC Biomarker and Other Nab(R) Pipeline Therapies at AACR Annual Meeting.
The Asthma and Allergy Foundation of America:New nationwide survey of 1,001 patients found most asthma patients know the risks of "uncontrolled asthma," but misinterpret asthma control, not realizing that asthma is a chronic disease that requires long-term therapy "“ even when symptoms are not present.
Results from three newly presented studies evaluating the maintenance combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dihydrate), showed significant improvement in small airway function in patients ages 12 years and older with asthma previously receiving inhaled corticosteroid (ICS) therapy.
A new study addresses the growing controversy among dental health professionals regarding the best course of treatment when evaluating between a root canal or dental implant procedure. Researchers evaluated the success and failure rates of teeth treated with a root canal (endodontically treated teeth) or extracted and replaced with a dental implant.
Data presented today from two pivotal efficacy and safety trials, SHINE and SUN, demonstrated that SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol significantly improved lung function and was well-tolerated in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD) relative to budesonide and formotorol administered alone, and placebo.
MedImmune announced today it will present nine abstracts at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th Annual Meeting of Infectious Disease Society of America (IDSA). These abstracts advance the knowledge about respiratory syncytial virus (RSV) and influenza, providing valuable insight into infectious disease prevention and underscoring MedImmune's leadership in this disease category.
A 5,000-person, five-country study released today by Edelman shows that people want more active, trusted, and personal health interaction with companies, organizations and brands, effectively rewriting the "rules of engagement" in health. The Edelman Health Engagement Barometer finds that to win a "license to engage," companies must, above all, help people address their specific personal health concerns and help them maintain their health through prevention and care. They also must provide people with thorough, transparent, and specific information; engage them through personal and health-expert channels, online and off; and address personal issues like health and well-being before larger societal concerns.
Five neonatology fellows have been awarded grants designed to stimulate interest and research in the area of follow-up care of the premature infant as part of MedImmune's Fellowship Program. The grants, which underscore MedImmune's commitment to expanding research within pediatric medicine, will provide each recipient's institution a $35,000 grant, totaling $175,000 in research funding. The five recipients were acknowledged on Sunday, October 12, 2008 at a reception coinciding with the American Academy of Pediatrics (AAP) 2008 National Conference and Exhibition.
MedImmune announced today it will present four abstracts at the American Academy of Pediatrics (AAP) 2008 National Conference & Exhibition that add to the company's growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of viral respiratory infection among preterm infants.
Newly released results from two previously published studies demonstrated patients receiving the maintenance combination asthma therapy SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol achieved bronchodilation, or opening of the airways, within 15 minutes and reported feeling their medication begin to work right away.
A 52-week study examined the long-term safety of the maintenance combination asthma therapy, SYMBICORT Inhalation Aerosol, at up to double the approved dosage. More than 700 patients ages 12 years and older with moderate to severe persistent asthma, and who had been previously treated with inhaled corticosteroids, participated in the study. Safety was evaluated through several assessments, including the incidence of asthma exacerbations and adverse events. The study showed that SYMBICORT, a combination of budesonide, an inhaled corticosteroid, and formoterol, a rapid and long-acting beta2-agonist, had a safety profile similar to one of its mono-components, budesonide.
AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the long-term maintenance treatment of asthma in pediatric patients ages 6 to 11 years old. SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.
Results from a pivotal Phase III clinical trial presented today demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior in preventing venous blood clots in patients who underwent total knee replacement (TKR) surgery. The head-to-head study compared rivaroxaban with the U.S.-approved dosing regimen for enoxaparin, the current standard of care. Data from the RECORD4 clinical trial were presented at the annual meeting of the European Federation of National Associations of Orthopaedics & Traumatology (EFORT). Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare AG.
A new 12-week study examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dehydrate) Inhalation Aerosol, in treating mild to moderate persistent asthma in children ages 6 to 15 years old who were previously treated with an inhaled corticosteroid (ICS).
Winners addressing critical issues including Parkinson's disease and global climate change.
A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure (ATSM).1 Patients participating in the study were ages 18 years and older with moderate to severe asthma and had been previously treated with inhaled corticosteroids.1 Results were presented today at the International Conference of the American Thoracic Society held in Toronto, May 16-21, 2008.
Asthma is a serious chronic medical condition. About 1.8 million ER visits per year and more than $16 billion in direct and indirect healthcare costs are attributable to the disease. For some, asthma can simply make breathing difficult, for others, it can be potentially life-threatening. Change of season can bring more than asthma triggers; learning to control disease is more than just managing symptoms.
Retrospective chart review in 10 geographic regions throughout the United States presented at Pediatric Academic Societies (PAS) annual meeting. The review evaluated the use of Synagis (palvizumab) as a preventative measure against RSV disease in high-risk infants.
In clinical trial, motavizumab reduced hospitalizations due to respiratory syncytial virus by 83 percent compared to placebo
Today, Cambridge-based biotech Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced the initiation of a multi-center, Phase 2a clinical trial of Azedra (Ultratrace iobenguane I-131 or Ultratrace MIBG) in high-risk pediatric neuroblastoma patients---a type of neuroendocrine cancer that primarily affects children. Occurring in about one in every 7,000 births, neuroblastoma is the most common solid tumor in children outside of the brain.
One4One, a unique program focused on empowering women to help make a difference in the fight against cervical cancer, starts today during National Minority Cancer Awareness Week. One4One urges women to talk to their healthcare provider about ways they can help protect themselves from cervical cancer, while also raising money to increase cervical cancer information programs and other educational services, especially for those who may be at greater risk of developing the disease due to lack of access to information or healthcare.
A recent survey of 202 neonatologists and pediatricians, which examined current attitudes and practices when caring for the specialized health needs of preterm infants, revealed that most respondents (70 percent) feel the United States' healthcare system does not place enough emphasis on or dedicate enough resources to preventive healthcare for preemies.
High doses of daily caffeine during pregnancy "“ whether from coffee, tea, caffeinated soda or hot chocolate -- cause an increased risk of miscarriage, according a new study by the Kaiser Permanente Division of Research. The study controlled, for the first time, pregnancy-related symptoms of nausea, vomiting and caffeine aversion that tended to interfere with the determination of caffeine's true effect on miscarriage risk.
Researcher who discovered telomerase's role in aging and cell mutation among five women scientists awarded in Paris.
Mothers who reported sleeping five hours or less per day when their babies were six months old had a threefold higher risk for substantial weight retention (11 pounds or more) at their baby's first birthday than moms who slept seven hours per day, according to a new study by Kaiser Permanente and Harvard Medical School / Harvard Pilgrim Health Care.
Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the presentation of Phase 2 clinical results demonstrating that LymphoStat-B® (belimumab) achieved a sustained improvement in disease activity across multiple clinical measures, decreased the frequency of disease flares over time, and was well tolerated through 2.5 years on treatment in combination with standard of care in patients with active systemic lupus erythematosus (SLE).
MedImmune, Inc. today announced it will present three abstracts at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, adding to the company's growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of hospitalization among infants.
According to a new survey released this week in conjunction with the National MS Society's National Conference, many people living with multiple sclerosis (MS) who experience visual, dexterity, and cognitive challenges report that technology plays a vital role in helping them live with the disease. However, relatively few are using the assistive technologies that could help them overcome many of these challenges.
The vast majority of patients who had a successful result with the percutaneous MitraClip device did not need mitral valve surgery three years after their procedure, and many benefited from significantly improved function of the left ventricle (commonly known as reverse remodeling), according to data presented this week at the Cardiovascular Research Foundation's (CRF) nineteenth annual Transcatheter Cardiovascular Therapeutics symposium.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right